🇺🇸 FDA
Patent

US 11312939

Constructs for chimeric antigen receptors

granted A61KA61K2239/13A61K2239/21

Quick answer

US patent 11312939 (Constructs for chimeric antigen receptors) held by Carisma Therapeutics Inc. expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Carisma Therapeutics Inc.
Grant date
Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2239/13, A61K2239/21, A61K2239/22, A61K38/00